Endocrine Abstracts

In acromegalic patients not suitable for first-line surgical treatment, pharmacotherapy is a valuable choice. Depot somatostatin analogs (SSA) represent efficacious and well-tolerated drugs; however, they normalize hormonal parameters in no more than 65–75%. Pegvisomant (PEGA), a GH receptor antagonist, has been shown to normalize IGF-I levels in more than 90% of patients. We report our experience in 13 acromegalic patients (7 M, 6 F; age: 50.2±3.9 yrs; 7 macroadenom...

Introduction: Acromegaly is a rare disease caused by chronic exposure to excessive levels of GH, usually related to the presence of a pituitary adenoma, and associated to somatic and visceral hypertrophy, metabolic alterations, respiratory and cardiovascular complications, and increased risk of neoplasias.Materials and methods: The prevalence of manifestations, complications and associated illness was evaluated in 137 acromegalic subjects (52 M, 85 F; ag...